Solid‐phase extraction treatment is required for measurement of active glucagon‐like peptide‐1 by enzyme‐linked immunosorbent assay kit affected by heterophilic antibodies

Hasegawa, Tomonori; Komagata, Miho; Hamasaki, Akihiro; Harada, Norio; Seino, Yutaka; Inagaki, Nobuya

doi:10.1111/jdi.12896

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, we measured the active GLP-1 and GIP following the manufacturers' instructions and did not perform extraction treatment. Recent studies have shown that interfering substances in blood could influence the assay for incretin hormones and ethanol or solid-phase extraction treatment is suitable for the more precise assays [35,36]. Therefore, our data include a potential problem overestimating ''biologically intact" incretin hormones.…”

Section: Discussionmentioning

confidence: 94%

Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin

Nakagawa

Nagai

Yamamoto

et al. 2019

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Glucagon has an important role in glucose homeostasis. Recently, a new plasma glucagon assay based on liquid chromatography-high resolution mass spectrometry was developed. We evaluated the influence of a dipeptidyl peptidase-4 inhibitor (anagliptin) on plasma glucagon levels in Japanese patients with type 2 diabetes by using this new assay. Methods: Twenty-four patients with type 2 diabetes were enrolled in a prospective, singlecenter, randomized, open-label study and were randomly allocated to 4 weeks of treatment with metformin (1000 mg/day) or anagliptin (200 mg/day). A liquid test meal labeled with sodium [ 13 C] acetate was ingested before and after the treatment period. Samples of blood and expired air were collected over 3 h. Plasma levels of glucose, glucagon, C-peptide, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured, and gastric emptying was also evaluated. Results: Twenty-two patients completed the study (metformin group: n = 10; anagliptin group: n = 12). Glycemic control showed similar improvement in both groups. In the anagliptin group, there was a slight decrease of the incremental area under the plasma concentration versus time curve for glucagon after the test meal (P = 0.048). In addition, the plasma level of active GLP-1 and GIP was increased, and plasma C-peptide was also increased versus baseline. Neither anagliptin nor metformin delayed gastric emptying. Conclusions: In patients with type 2 diabetes maintained endogenous insulin secretion, anagliptin increased the plasma level of active GLP-1 and GIP in association with a slight stimulation of insulin secretion and slight inhibition of glucagon secretion, but did not delay gastric emptying.

show abstract

Section: Discussionmentioning

confidence: 94%

Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin

Nakagawa

Nagai

Yamamoto

et al. 2019

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Total gastric inhibitory peptide (GIP) and GLP-1 concentrations were evaluated using a human total GIP enzyme-linked immunosorbent assay (ELISA) kit (Linco Research, St Charles, MO, USA) and human total GLP-1 ELISA kit (Meso Scale Discovery, Gaithersburg, MD, USA), respectively as previously described ( 28 , 29 ). After solid phase extraction ( 30 , 31 ), the concentration of GIP and GLP-1 in their active forms ware measured using a human active GIP ELISA kit (IBL Co Ltd, Fujioka, Japan) and a human active GLP-1 ELISA kit (Millipore, Billerica, MA, USA), respectively.…”

Section: Methodsmentioning

confidence: 99%

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects

Hamasaki,

Harada,

Muraoka

et al. 2024

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

IntroductionIncretin-based drugs are extensively utilized in the treatment of type 2 diabetes (T2D), with remarkable clinical efficacy. These drugs were developed based on findings that the incretin effect is reduced in T2D. The incretin effect in East Asians, whose pancreatic β-cell function is more vulnerable than that in Caucasians, however, has not been fully examined. In this study, we investigated the effects of incretin in Japanese subjects.MethodsA total of 28 Japanese subjects (14 with normal glucose tolerance [NGT], 6 with impaired glucose tolerance, and 8 with T2D) were enrolled. Isoglycemic oral (75 g glucose tolerance test) and intravenous glucose were administered. The numerical incretin effect and gastrointestinally-mediated glucose disposal (GIGD) were calculated by measuring the plasma glucose and entero-pancreatic hormone concentrations.Results and discussionThe difference in the numerical incretin effect among the groups was relatively small. The numerical incretin effect significantly negatively correlated with the body mass index (BMI). GIGD was significantly lower in participants with T2D than in those with NGT, and significantly negatively correlated with the area under the curve (AUC)-glucose, BMI, and AUC-glucagon. Incretin concentrations did not differ significantly among the groups. We demonstrate that in Japanese subjects, obesity has a greater effect than glucose tolerance on the numerical incretin effect, whereas GIGD is diminished in individuals with both glucose intolerance and obesity. These findings indicate variances as well as commonalities between East Asians and Caucasians in the manifestation of incretin effects on pancreatic β-cell function and the integrated capacity to handle glucose.

show abstract

“…Active GLP-1 levels were determined from frozen plasma using a commercially available enzyme-linked immunosorbent assay kit (EGLP-35K, Millipore, Billerica, MA) in accordance with the manufacturer's instructions. Note that we did not perform solidphase extraction, and cross-reactivity of antibodies may have resulted in higher measured active GLP-1 [33]. Plasma FFAs were determined by the enzymatic colorimetric method (NEFA C test kit; Wako Chemicals, Neuss, Germany).…”

Section: Laboratory Analysesmentioning

confidence: 99%

The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity

Gilijamse

Demirkıran

Wagensveld

et al. 2021

Surgery for Obesity and Related Diseases

View full text Add to dashboard Cite

Background: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is beneficial for the human glucose metabolism, and GLP-1 secretion is greatly enhanced following Roux-en-Y gastric bypass (RYGB). Objectives: To elucidate the relationship between GLP-1 concentrations and insulin sensitivity in subjects with class II/III obesity without diabetes and to assess the relation between GLP-1 and the improvements in glucose metabolism following RYGB. Setting: Clinical research facility in a university hospital. Methods: We recruited 35 patients scheduled for RYGB and assessed their plasma GLP-1, insulin, and glucose responses to a high-fat mixed meal. Basal and insulin-mediated glucose fluxes were determined during a 2-step hyperinsulinemic-euglycemic clamp with stable isotope-labeled tracers. Out of 35 subjects, 10 were studied both before surgery and at 1 year of follow-up. Results: Plasma GLP-1 increased following the high-fat mixed meal. Postprandial GLP-1 excursions correlated positively with hepatic and peripheral insulin sensitivity, but not with body mass index. At 1 year after RYGB, participants had lost 24% 6 6% of their body weight. Plasma GLP-1, insulin, and glucose levels peaked earlier and higher after the mixed meal. The positive association between the postprandial GLP-1 response and peripheral insulin sensitivity persisted. Conclusions: Postprandial GLP-1 concentrations correlate with insulin sensitivity in subjects with class II/III obesity without diabetes before and 1 year after RYGB. Increased GLP-1 signaling in postbariatric patients may, directly or indirectly, contribute to the observed improvements in insulin sensitivity and metabolic health. (Surg Obes Relat Dis 2021;-:1-9.

show abstract

Solid‐phase extraction treatment is required for measurement of active glucagon‐like peptide‐1 by enzyme‐linked immunosorbent assay kit affected by heterophilic antibodies

Abstract: Substances absorbed to a heterophilic blocking tube carrier might interfere with an active GLP-1 immunoassay. Solid-phase extraction treatment is required for measurement of active GLP-1 by an ELISA kit affected by heterophilic antibodies.

Cited by 4 publications

References 21 publications

Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin

Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects

The relation between postprandial glucagon-like peptide-1 release and insulin sensitivity before and after bariatric surgery in humans with class II/III obesity

Contact Info

Product

Resources

About